Retinalamin® is is a drug with the proven cellular and molecular effectiveness.

Retinalamin® is a retinoprotector that produces a direct effect on the retina. It launches mechanisms of adaptation to pathological processes and regeneration of retinal neurons improving visual functions in case of glaucoma, diabetic retinopathy and other eye disorders.

The mechanism of action is determined by the metabolic activity of Retinalamin®:

  • The drug is known to activate eye tissue metabolism;
  • Normalize the functions of cellular membranes;
  • Improve intracellular synthesis of protein;
  • Regulate the processes of lipid peroxide oxidation;
  • Inhibit inflammatory processes;
  • Normalize vascular permeability;
  • Promote faster healing of injured tissues.

According to the description, Retinalamin® is indicated for:

  • Compensated primary open-angle glaucoma;
  • Diabetic retinopathy;
  • Post-traumatic and post-inflammatory central retinal dystrophy;
  • Myopia (within comprehensive treatment);
  • Dystrophic diseases of the retina.

Dosage and Administration

It is recommended to use the medicine only after a doctor's examination and upon prescription. Administration of Retinalamin® is carried out either intramuscularly or through the skin of the upper eyelid. The depth of an injection is about 1 cm.

The drug should be diluted with 1-2 ml of sodium chloride liquid (0.9%). To prevent foaming, the needle should be pointed closer to the wall of the vial.

The dose and scheme of use depend on the disease and the condition of the patient. Please refer to the official description for the detailed information on the drug administration.


  • individual hypersensitivity;
  • patients under 18 y.o.;
  • pregnancy.


Caution should be taken when driving vehicles and operating machinery during the treatment. Parabulbar injections must be carried out by a qualified medical worker. Always follow the description and your doctor's recommendations.